Seres Therapeutics (MCRB) Accumulated Expenses (2014 - 2026)

Seres Therapeutics has reported Accumulated Expenses for 13 years, with the latest figure at $2.9 million in Q1 2026.

• Quarterly Accumulated Expenses fell 53.97% year-over-year to $2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.9 million (down 53.97% YoY) and the FY2025 annual result came in at $4.0 million, down 48.12% from the prior year.
• Accumulated Expenses fell to $2.9 million in Q1 2026 per MCRB's latest filing, from $4.0 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $86.4 million in Q2 2024 and troughed at $2.9 million in Q1 2026.
• A 5-year average of $33.5 million and a median of $22.5 million in 2023 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2025: Accumulated Expenses jumped 1575.74% in 2022, then plunged 93.27% in 2025.
• Over 5 years, Accumulated Expenses stood at $59.8 million in 2022, then plunged by 62.38% to $22.5 million in 2023, then slumped by 65.99% to $7.7 million in 2024, then slumped by 48.12% to $4.0 million in 2025, then decreased by 27.92% to $2.9 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $2.9 million, $4.0 million, and $6.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.